Revance (RVNC) Announces Results From the RT002 Ph 1/2 Study
Tweet Send to a Friend
Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
